Prezista (darunavir) is an antiretroviral medicine used as part of combination treatment for HIV-1 infection. It belongs to the protease inhibitor class and works by blocking the HIV protease enzyme, which the virus needs to produce new, mature, and infectious particles.
Darunavir is a second-generation protease inhibitor that retains activity against many HIV strains resistant to earlier protease inhibitors. It must always be given with a pharmacokinetic booster: either ritonavir (Norvir) or cobicistat (as in the combined tablet Prezcobix).
Back To Top
Prezista must always be taken with a booster: either ritonavir 100 mg or cobicistat 150 mg.
Take with food at the same time each day. Swallow tablets whole.
The correct Prezista dose depends on your treatment history and resistance profile. Your HIV doctor will determine the right dose and schedule for your individual situation.
Back To Top
Take the missed dose with food as soon as you remember. If it is nearly time for the next dose, skip and continue your schedule. Never take a double dose.
Back To Top
Contact your HIV specialist or a poison control centre.
Back To Top
Common side effects:
Less common but important:
Regular monitoring of blood lipids, liver function, kidney function, and viral load is required.
Back To Top
Prezista is always taken with ritonavir (or cobicistat), which acts as a booster. This booster slows the breakdown of darunavir in your body so it stays at effective levels but it also affects how your liver processes many other medicines, which is why interactions are more common with Prezista than some other HIV treatments.
Why does darunavir need a booster?
Darunavir is broken down quickly by liver enzymes if taken alone. Without a booster, the dose required to maintain sufficient blood levels would be very large and impractical. Adding ritonavir or cobicistat at a low dose blocks the enzyme responsible, extending darunavir's time in the body and allowing a much lower dose to be effective. This approach, called pharmacokinetic boosting, is used with several HIV protease inhibitors.
Is Prezista effective against resistant HIV?
Yes. Darunavir is specifically designed to bind tightly to the HIV protease enzyme even when some resistance mutations are present. It requires accumulation of multiple specific mutations (at least three of a defined set) before resistance becomes clinically significant, giving it a higher genetic barrier to resistance than older protease inhibitors.
Back To Top
Ace provides accurate and independent information medically reviewed on prescription medications. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Back To Top